Pharma Marketletter - Eisai/Pfizer’s Aricept shows significant benefits for dementia caused by stroke.
Treatment with Aricept (donepezil) significantly improved memory, thinking and global function in patients with vascular dementia compared with placebo, according to an article published in this month’s issue of the peer-reviewed journal Neurology.
Related Results
Health: A ricept isn’t a cure, but it has made me a different
Health: Memories are made of this
Eisai bolsters its sales team to promote CNS products, increase independence
No better memor-E
It's head-to-head competition among drugs for Alzheimer's
The drug, which was discovered by Japan’s Eisai and is co-marketed with Pfizer, achieved turnover of some $1 billion in 2002 in its currently-approved indication for the treatment of Alzheimer’s disease. VaD, a cognitive decline caused by a single, localized stroke, or series of strokes, is the second most common form of dementia in the USA. The study examined the efficacy and safety of the …
Want to read the whole article? You can purchase it here. It’s quick and easy.
